High Demand for Medications for the Treatment of Depression and Daytime Sleepiness!
The treatment of depression, daytime sleepiness, and migraines is likely to open up increasing revenues for Axsome Therapeutics Inc. in the long term!
Reading Time: 1 minute
Biotechnology companies are currently attracting increasing interest from investors. Particularly those stocks that either already have approved medications or those that are positioned with promising procedures or for complex diseases. In this context, Axsome Therapeutics Inc. (AXSM) can draw attention on August 4th after the presentation of the Q2 report. The company reported a revenue increase of 72.1% year-over-year to $150.04 million. Compared to the previous quarter, it is a growth of 24%. This robust growth underscores the strong demand for...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
